July 29, 2026 | Breaking News
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
Antibody Drug Conjugates Reimagined
Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders. Our state-of-the-art platform results in highly specific delivery of degraders to target tissue.
Firefly lights the way
Accessing new classes of ADC payloads requires new technology. At Firefly, we have developed a proprietary platform to capture this opportunity at scale.
Diverse minds, bright sparks
Firefly is a team of innovators from diverse backgrounds. We are dedicated to exploring complex and exciting challenges.
We're looking for
Impactful Dependable Collaborative Positive
individuals to join our quest!
Firefly News
Keep up to date with what’s happening at Firefly!
February 15, 2024 | Press Release